Method and device for utilizing analyte levels to assist in the treatment of diabetes
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
G01N-033/48
G01N-031/00
G06G-007/48
G06G-007/58
출원번호
US-0528997
(2006-09-28)
등록번호
US-8718943
(2014-05-06)
발명자
/ 주소
Moerman, Piet
출원인 / 주소
Abbott Diabetes Care Inc.
대리인 / 주소
Baba, Edward J.
인용정보
피인용 횟수 :
0인용 특허 :
5
초록▼
A health-monitoring device assesses the health of a user based on levels of two analytes in a biological fluid. A first analyte that is utilized to assess a user's health is a fat metabolism analyte, such as ketones, free fatty acids and glycerol, which is indicative of fat metabolism. A second anal
A health-monitoring device assesses the health of a user based on levels of two analytes in a biological fluid. A first analyte that is utilized to assess a user's health is a fat metabolism analyte, such as ketones, free fatty acids and glycerol, which is indicative of fat metabolism. A second analyte that is utilized is a glucose metabolism analyte, such as glucose. The levels of the two analytes may be used to assess insulin sensitivity, to detect both recent hypoglycemia and the cause of high glucose levels, and/or to guide therapeutic intervention.
대표청구항▼
1. A computer-implemented method of assessing an insulin activity error and its effect on glucose levels, the method comprising the computer-implemented steps of: measuring an amount of a fat metabolism analyte in a biological fluid sample and an amount of a glucose metabolism analyte in the biologi
1. A computer-implemented method of assessing an insulin activity error and its effect on glucose levels, the method comprising the computer-implemented steps of: measuring an amount of a fat metabolism analyte in a biological fluid sample and an amount of a glucose metabolism analyte in the biological fluid sample,determining, using a computer, a real insulin activity level, wherein the real insulin activity level comprises a reciprocal conversion of the amount of the fat metabolism analyte in the biological fluid sample,comparing, using the computer, the real insulin activity level with a theoretical insulin activity level to calculate the insulin activity error; andpredicting, using the computer, a prospective glucose level using the amount of the glucose metabolism analyte in the biological fluid and the calculated insulin activity error,wherein a positive insulin activity error is predictive of a glucose level which is lower than that predicted by the theoretical insulin activity level, andwherein a negative insulin activity error is predictive of a glucose level which is higher than that predicted by the theoretical insulin activity level. 2. The method of claim 1, wherein the fat metabolism analyte is selected from the group consisting of ketones, glycerol, free fatty acids and a fatty acid indicative of free fatty acid levels. 3. The method of claim 1, wherein the glucose metabolism analyte is selected from the group consisting of glucose, pyruvate, glucose-6-phosphate and lactate. 4. The method of claim 1, wherein the sample comprises one of blood, a derivate of blood, interstitial fluid, urine and saliva. 5. The method of claim 1, wherein the step of predicting a prospective glucose level comprises predicting a likelihood of a user developing one of hypoglycaemia and hyperglycaemia. 6. The method of claim 1, wherein the method comprises a retrospective diagnosis of one of hypoglycaemia and hyperglycaemia. 7. The method of claim 1 wherein the method comprises recommending a timing for a future determination of analyte levels in a user. 8. A computer-implemented method of predicting a user's glucose levels in the future, the method comprising the computer-implemented steps of: measuring an amount of a fat metabolism analyte in a biological fluid sample and an amount of a glucose metabolism analyte in the biological fluid sample,determining, using a computer, a real insulin activity level in the user, wherein the real insulin activity level comprises a reciprocal conversion of the amount of the fat metabolism analyte in the biological fluid sample;comparing, using the computer, the real insulin activity level with a theoretical insulin activity level to calculate an insulin activity error; andrunning, using the computer, a glucose prediction algorithm corrected for the insulin activity error, wherein the correction comprises decreasing a glucose level predicted by the theoretical insulin activity when the insulin activity error is positive and increasing a glucose level predicted by the theoretical insulin activity when the insulin activity error is negative, the algorithm taking into consideration an additional parameter comprising at least one of: body mass index, gender, meal intake, medication, exercise duration and intensity, alcohol consumption and weight. 9. The method of claim 8, further comprising the step of: calculating, using the computer, a likelihood of the user developing one of hypoglycaemia and hyperglycaemia. 10. The method of claim 8, further comprising the step of: calculating, using the computer, a likelihood of one of a past hypoglycaemia incident and a past hyperglycaemia incident. 11. The method of claim 8, further comprising the step of: formulating test frequency advice to the user. 12. The method of claim 8, further comprising the step of: formulating medication dosing advice to the user. 13. The method of claim 8, further comprising the step of: automatically communicating insulin dose information to an insulin delivery device. 14. A health-monitoring device comprising: a test element configured to receive a biological fluid sample and measure: an amount of a fat metabolism analyte in the biological fluid sample, andan amount of a glucose metabolism analyte in the biological fluid sample;a processor programmed to: assess a real insulin activity level of a user, wherein the real insulin activity level comprises a reciprocal conversion of the amount of the fat metabolism analyte in the biological fluid sample,compare the real insulin activity level with a theoretical insulin activity level to calculate an insulin activity error, andpredict a prospective glucose level using the amount of the glucose metabolism analyte in the biological fluid and the calculated insulin activity error,wherein a positive insulin activity error is predictive of a glucose level which is lower than that predicted by the theoretical insulin activity level, andwherein a negative insulin activity error is predictive of a glucose level which is higher than that predicted by the theoretical insulin activity level; anda display device for displaying the real insulin activity level, the insulin activity error, or the prospective glucose level. 15. The device of claim 14, wherein the test element comprises one or more of a photometric, reflectometric, electrochemical and fluorescence based system for analyzing the biological fluid sample. 16. The device of claim 14, wherein a single test element measures both an amount of a fat metabolism analyte in the biological fluid sample and an amount of a glucose metabolism analyte in the biological fluid sample. 17. The device of claim 14, wherein the device automatically or continuously measures the glucose metabolism analyte. 18. The device of claim 14, wherein the device automatically or continuously measures the fat metabolism analyte. 19. The device of claim 14, further comprising: a memory element for tracking the evolution of one of the real insulin activity level and the insulin activity error for the user. 20. The method of claim 1, wherein the fat metabolism analyte is a ketone and the glucose metabolism analyte is glucose. 21. The method of claim 1, wherein the biological fluid sample is an extracted biological fluid sample. 22. The device of claim 14, wherein the test element comprises an electrochemical based system for analyzing the biological fluid sample. 23. The device of claim 22, wherein the test element comprises a test strip. 24. The device of claim 14, wherein the test element comprises a test strip. 25. The device of claim 16, wherein the test element comprises a test strip. 26. The device of claim 14, wherein the test element comprises a skin-inserted device. 27. The device of claim 14, wherein the test element comprises a non-invasive measurement device. 28. The method of claim 8, wherein the measuring is performed with a test element configured to contact the biological fluid sample. 29. The method of claim 28, wherein the test element comprises a test strip. 30. The method of claim 29, wherein the test strip is an electrochemical-based test strip. 31. The method of claim 30, wherein the test strip is configured to measure both the amount of the fat metabolism analyte and the amount of the glucose metabolism analyte. 32. The method of claim 28, wherein the test element comprises a skin-inserted device. 33. The method of claim 28, wherein the test element comprises a non-invasive measurement device.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (5)
Harding John D. (Ben Lomond CA), Adjustable tip for lancet device.
Bcker Dirk (Heidelberg DEX) Haar Hans-Peter (Wiesloch DEX) Blasberg Peter (Weinheim DEX) Kotulla Reinhard (Lambsheim DEX), Analytical system for monitoring a substance to be analyzed in patient-blood.
Surwit Richard S. ; Allen ; III Lyle M. ; Cummings Sandra E., Systems, methods and computer program products for monitoring, diagnosing and treating medical conditions of remotely located patients.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.